Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions

NCT04400682 is registered in ClinicalTrials.gov with Novelfarma Ilaç San. ve Tic. Ltd. Sti. as lead sponsor.

NCT NCT04400682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions
Lead sponsor
Novelfarma Ilaç San. ve Tic. Ltd. Sti.
Phase
Phase 1
Overall status
Completed
Start date
May 28, 2020
Completion date
June 18, 2020
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence